In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.

On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.

Ikena, Senti and others look to clinical presentations at AACR.

Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.

The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.

The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.

The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.

Skyscraper-01 stars at AACR's upcoming clinical trial plenary.

The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.